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Many countries have implemented infection control mea-
sures directed at carriers of multidrug-resistant organisms. 
To explore the ethical implications of these measures, we 
analyzed 227 consultations about multidrug resistance and 
compared them with the literature on communicable disease 
in general. We found that control measures aimed at carri-
ers have a range of negative implications. Although moral 
dilemmas seem similar to those encountered while imple-
menting control measures for other infectious diseases, 4 
distinct features stand out for carriage of multidrug-resistant 
organisms: carriage presents itself as a state of being; car-
riage has limited relevance for the health of the carrier; car-
riage has little relevance outside healthcare settings; and 
antimicrobial resistance is a slowly evolving threat on which 
individual carriers have limited effect. These features are of 
ethical relevance because they influence the way we tradi-
tionally think about infectious disease control and urge us 
to pay more attention to the personal experience of the in-
dividual carrier.
Antimicrobial resistance (AMR) is one of the most se-rious health threats of the 21st century. It challenges 
effective treatment of infectious diseases, now and in the 
future. AMR may imply that infections that used to be rela-
tively harmless will pose a severe threat to patients in the 
future (1). Many countries have implemented measures to 
control AMR, including proper use of antimicrobial drugs 
in humans, minimization of antimicrobial drug use in ani-
mals, and prevention of further transmission of resistant 
microbes within the healthcare system (1–5). AMR raises 
a range of ethical questions (6–12). We explored ethical is-
sues that arise in relation to carriage of antimicrobial drug–
resistant organisms (hereafter called carriage).
AMR control measures are directed at carriers. The 
types of control measures vary by microorganism and 
depend on resistance pattern, virulence, and mode of trans-
mission. Measures can include control precautions taken 
during patient care, such as use of personal protective 
equipment; cleaning and disinfection of the care environ-
ment; dedicated single-patient use of rooms and equipment; 
eradication treatment, if applicable; and, in exceptional 
cases, exclusion of the carrier from work or joint facilities. 
The actual control measures recommended by health au-
thorities vary among countries. Countries in northern Eu-
rope, for instance, have implemented far-reaching infection 
control interventions that include preemptive use of con-
tact precautions at the time of admission until the patient is 
proven culture negative and closure of hospital units to new 
admissions when applicable. Countries in southern Europe 
and North America follow a less aggressive approach, em-
phasizing contact precautions after detection of multidrug-
resistant organisms (1–4).
Control measures may effectively control transmission 
of multidrug-resistant organisms, but negative effects on 
the health and well-being of carriers have been reported 
from countries that follow stringent multidrug-resistant 
organism policies and from countries that have a less ag-
gressive approach (13–16). These negative effects make 
AMR control measures, apart from a technical and medical 
challenge, also an ethical issue. Our aim with this study 
was to examine the ethical context of multidrug-resistant 
organism carriage: what are the negative implications for 
carriers, and what is the ethical relevance?
Methods
We analyzed 227 consultations/inquiries associated with 
multidrug-resistant organisms registered from January 1, 
2008, through January 16, 2016, by the Centre for Infec-
tious Disease Control in the Netherlands (Table 1; Figure). 
We looked for potentially negative implications on freedom, 
well-being, and other ethical values and assessed the respects 
in which the ethically relevant features of carriage differ 
from those of infectious disease in general. The Netherlands 
follows a strict multidrug-resistant organism search-and-de-
stroy policy (Table 2) (2,17,18). Estimated prevalence rates 
for multidrug-resistant organisms in the Netherlands are low 
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(online Technical Appendix, https://wwwnc.cdc.gov/EID/
article/24/9/17-1644-Techapp1.pdf) (2,19–21).
Results
Negative Implications of Control Measures for Carriers
Problems with Access to Healthcare
A clear implication of AMR control measures involves 
problems with access to healthcare. During their consulta-
tions, several carriers asked about being faced with post-
ponement of planned surgery, about cancellation of ad-
mission to rehabilitation, and about being denied access 
to dental clinics. A nursing home, for instance, wanted to 
deprioritize a person at the top of the waiting list because 
this person was carrying a multidrug-resistant organism. A 
medical daycare center refused to admit a child because of 
persistent carriage.
Restrictions within Healthcare Facilities
Another distinct implication of AMR control measures in-
volves restrictions within healthcare facilities. Several con-
sultations involved questions about carriers of methicillin-
resistant Staphylococcus aureus (MRSA) in care facilities 
in which elderly carriers were banned from organized so-
cial activities or not allowed to dine at the same table with 
fellow residents. In medical daycare facilities, children 
who were carriers were banned from group activities or 
kept away from their peers, and in a psychiatric institution, 
a group of patients was placed in a closed ward because of 
carriage. Other inquiries concerned privileges that carriers 
received; for instance, carriers in nursing homes were al-
located a single room or a private bathroom.
Negative Implications for Daily Life
The control measures also affected daily life. One inquiry 
concerned a MRSA-positive child who faced restrictions 
after returning to school because a classmate was a cys-
tic fibrosis patient for whom acquiring a MRSA infection 
would constitute a health risk. Another inquiry was about 
adoption of a child with special health needs; the family had 
already adopted their first child with a previous diagnosis 
of persistent MRSA carriage, and they hesitated to adopt 
a second child because the MRSA would most likely be 
transmitted to that child, bringing extra MRSA-associated 
health risks. Also, parents of a healthy MRSA toddler were 
confronted with a daycare center caregiver who refused to 
attend to their child for fear of transmitting MRSA to her 
newborn baby at home. Some inquiries concerned interac-
tion with animals; for instance, a family struggled with per-
sistent MRSA carriage and 1 of their children was denied 
access to a medical daycare center. They were advised to 
relocate or abandon their cats, which were thought to be the 
source of reinfection.
Negative Implications for Carriers Who Work in Healthcare
Control measures can also have negative implications for 
those who work in healthcare. We found cases of health-
care workers (HCWs) who were restricted at work, banned 
from work, and faced income loss. For example, a nurse 
who was a carrier was assigned administrative tasks instead 
of patient care, thereby missing out on the substantial finan-
cial benefits that come along with performing patient care 
during night and weekend shifts. A temporary employee’s 
contract was not renewed because of past carriage, and a 
fifth-year medical student discontinued training because 
of a chronic MRSA infection. HCWs were also pressed to 
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Table 1. Detailed information from 227 consultations about antimicrobial-resistant organisms, Centre for Infectious Disease Control, 
Bilthoven, the Netherlands, January 1, 2008–January 16, 2016* 
Characteristic No. (%) 
Type of multidrug-resistant organism  
 Methicillin-resistant Staphylococcus aureus 177 (78) 
 Vancomycin-resistant Enterococci 18 (8) 
 Extended-spectrum β-lactamase 9 (4) 
 Klebsiella pneumoniae carbapenemase-producing Enterobactericeae 5 (2) 
 Unknown 18 (8) 
Setting  
 Long-term care facilities 61 (27) 
 Paramedical facilities 23 (10) 
 Home-care facilities 14 (6) 
 Rehabilitation centers 5 (2) 
 Carriage among healthcare workers 50 (22) 
 Social interaction of healthcare workers 32 (14) 
 Other 42 (19) 
*In the Netherlands, 25 regional Public Health Services (PHS) are in charge of communicable disease control. Healthcare institutions such as hospitals 
and nursing homes have a responsibility to detect, monitor, and control outbreaks within their facility and report these to the PHS. The PHS assists 
healthcare institutions and professionals and provides advice on the basis of national guidelines. In turn, the Centre for Infectious Disease Control of the 
National Institute of Public Health and the Environment (RIVM) acts as national public health authority; it develops and publishes national guidelines and 
offers support in outbreak management including a 24-hour consultation helpdesk for PHS and other health professionals. The center is consulted by 
PHS professionals >1,000 times/y about a variety of cases of notifiable diseases, outbreaks, and incidents that occur in the community (15,17,18). Since 
2008, all consultations have been anonymously registered in a database. During the 8-year study period, RIVM registered 227 consultations associated 
with carriage of multidrug-resistant organisms that needed national guidance. 
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cooperate with testing and treatment. A temporary health-
care employee was asked to show proof of being MRSA 
negative, and MRSA-positive nurses were pressed to co-
operate with intensive eradication treatment consisting of 
daily scrubbing of the skin and taking of oral antimicrobial 
drugs. In several instances, MRSA-negative HCWs were 
excluded from healthcare work because in their private life 
they cared for a MRSA-positive child or parent.
Negative Implications for Close Contacts of HCWs
Infection control measures for HCWs can also affect their 
family members and other contacts. For example, HCWs 
with MRSA were asked to disclose the names of their 
close contacts outside the hospital. Contacts needed to 
cooperate with MRSA screening and, if test results were 
positive, undergo eradication treatment. In some instanc-
es, such measures had far-reaching consequences for fam-
ily members. For instance, in a single-income household, 
young children were subjected to very intensive MRSA 
eradication in order for the main breadwinner to be able 
to secure employment. In another case, contact screen-
ing started by the employer of a nurse who was a car-
rier included screening of the nurse’s children. One child 
was physically handicapped and visited a medical daycare 
center. When results indicated that he was a carrier, he 
was denied access to this medical daycare center for sev-
eral months.
The negative implications for carriers of multidrug-re-
sistant organisms were not only defined by the outcome of 
the control measures advised in the policies but also were 
further enhanced by focus on collective benefits with less 
emphasis on harm for carriers (1) and by strong concerns 
with communication and disclosure when applying the 
policy (2). Several inquiries resulted in implementation of 
control measures that were more stringent than those pre-
scribed by national policies.
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Figure. Methods used in study 
of ethics of infection control 
measures for carriers of 
antimicrobial-resistant organisms, 
the Netherlands, January 1, 
2008–January 16, 2016. MDRO, 
multidrug-resistant organism.
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Negative Implications because of Overemphasis on 
Collective Benefits
Inquiries reflected a strong focus on the benefits of AMR 
control measures and ignoring of the potential harm for 
carriers. Several inquiries reported control measures that 
went beyond the already stringent national policies. For ex-
ample, in 2015–2016, a large influx of war refugees from 
Syria to the Netherlands caused some hospitals to demand 
that their employees refrain from volunteer work with refu-
gees outside their working hours because of the possibility 
that they could be exposed to a multidrug-resistant organ-
ism by doing such work. In addition, a pig farmer who had 
undergone heart valve surgery was advised not to go back 
to work on the farm because of the small risk of contracting 
livestock-associated MRSA, which would make follow-up 
visits more complicated to schedule for the hospital.
Negative Implications because of Concerns about 
Communication and Disclosure
Some inquiries reflected outcomes that were motivated 
by concerns about disclosure and communication rather 
than actual risk for transmission of the multidrug-resistant 
organisms. For instance, a MRSA-positive child was not 
allowed access to a medical daycare facility, not because 
of the risk to other children, which was considered to be 
small, but because the facility felt an obligation to inform 
all other parents. The parents of the carrier, however, in-
sisted on nondisclosure for fear of stigma. Another inquiry 
concerned a nurse who lived on a livestock farm and was 
therefore at high risk of contracting MRSA, a risk that was 
well-known and had been accepted by her employer for 
years. When, by accident, the nurse was screened and car-
riage was confirmed, she was no longer allowed to work at 
that facility. This response was not motivated by the risk 
for transmission—the employer acknowledged that she 
presumably had been carrying MRSA for a long time and 
had never caused an outbreak—but because the institution 
was concerned about the consequences should MRSA car-
riage of a hospital employee become public.
Ethical Features Unique to Being a  
Multidrug-Resistant Organism Carrier
Inquiries concerned questions about AMR control mea-
sures that primarily aimed to reduce further transmission 
of antimicrobial-resistant pathogens. In doing so, these 
measures resulted in negative implications that raised 
moral dilemmas.
In the inquiries explored, the exact nature of the moral 
dilemmas remained implicit. However, for almost all cases, 
it could be assumed that the control measures had negative 
effects on the carrier’s well-being, autonomy, and (health-
associated) justice. Well-being was affected because carri-
ers were limited in their opportunities to work or to engage 
in social contacts. Autonomy may have been at stake when 
carriers were requested to disclose their medical condition 
or when they were pressed to undergo tests and eradication 
therapy they might have preferred to avoid. Their sense of 
dignity may have been affected when carriers were stig-
matized because of their condition. The various implica-
tions also seemed to be involve injustices: health inequity 
if carriers were excluded from certain medical treatment 
or faced a delay in care, and social injustice if they were 
excluded from (the benefits of) going to work.
Although challenging, the moral dilemmas at hand—
and the values at stake—seem not fundamentally different 
from dilemmas that arise in infectious disease control in 
general (22–25). Health equity issues, for instance, oc-
cur in many contexts of infectious disease control. In Eu-
rope, while the 2014–2015 Ebola outbreak was occurring 
in West Africa, persons suspected of having Ebola virus 
disease were banned from hospital emergency rooms (26). 
Often at the heart of outbreak management are quarantine, 
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Table 2. Indications for routine screening for multidrug-resistant organisms, the Netherlands* 
Healthcare setting Indication† 
Hospital Patients at high risk of carrying an MDRO (e.g., patients transferred from a hospital in a foreign country 
or patients working in animal husbandry) 
Patients at high risk of acquiring infection with an MDRO 
Patients with signs of clinical infection with an MDRO 
Patients for whom empiric treatment failed 
Patients with recurrent infection 
Family members of hospital patient known to carry an MDRO 
Personnel with unprotected exposure to a person known to carry MRSA 
General practice Patients for whom empiric treatment failed 
Patients with recurrent infection 
Nursing home/care facility Patients for whom empiric treatment failed 
Patients with recurrent infection 
Patient with unprotected exposure (e.g., shared a room, shared medical equipment) to a person with 
MRSA or carbapenemase-producing Enterobacteriaceae 
Personnel with unprotected exposure to a person known to carry MRSA 
Home Personnel with unprotected exposure to a person known to carry MRSA 
*MDRO, multidrug-resistant organism; MRSA, methicillin-resistant Staphylococcus aureus. 
†As advised by the Werkgroep Infectie Preventie guideline on measures against transmission of highly resistant microorganisms in hospitals (2,19,20). 
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isolation, and social distancing measures, which clearly 
involve tensions with respect to autonomy and deprive 
persons from contact with their loved ones and otherwise 
undermine their quality of life (25). Restrictions to health-
care staff (e.g., a surgeon who seems to be a hepatitis B 
virus carrier) are well-accepted ways to prevent bloodborne 
nosocomial infections (27). However, 4 differences stood 
out, suggesting that there is something ethically notewor-
thy about carriage of multidrug-resistant organisms.
Relevance of Carriage for the Carriers
Patients in this study were asymptomatic carriers for whom 
carriage did not affect their health. Some might have had 
other health conditions, but they were not ill from the drug-
resistant microorganism they carried. Thus, carriage differs 
from most communicable diseases, in which the health of 
the persons carrying the microorganism is threatened or af-
fected by the infection. Ebola virus infection, for instance, 
forms an acute threat to the health of the patient, who is in 
immediate need of treatment and medication while threat-
ening the health of others, including health personnel. 
Other infectious diseases can also involve asymptomatic 
carriage; moreover, multidrug-resistant organisms can cer-
tainly also cause infections and thus illness. In fact, the pro-
active screening and preemptive use of control measures 
that are common in the Netherlands probably caused an 
overrepresentation of inquiries concerning these “carriers 
without multidrug-resistant organism infection” (2,19,20). 
What remains ethically noteworthy and relevant for pre-
emptive and reactive AMR control strategies is that, al-
though all carriers are at risk for their carriage resulting in 
clinical infection, multidrug-resistant organisms primarily 
threaten a specific subgroup of vulnerable patients in hos-
pital settings. The extent to which multidrug-resistant or-
ganisms contribute to death has been debated and seems to 
remain limited to those with severe illness and concurrent 
conditions (28–30). Studies addressing multidrug-resistant 
gram-negative infections, for instance, show substantial di-
versity in the outcomes. It can be concluded that mortality 
rates are higher among those infected by multidrug-resis-
tant gram-negative bacteria; however, concurrent condi-
tions and severity scores are more commonly identified as 
predictors of death (28–30). From a broader public health 
perspective, the health threat of multidrug-resistant organ-
ism carriage thus appears limited.
Healthcare-Associated Relevance
A noteworthy finding is that carriage became relevant 
almost exclusively in healthcare-associated settings. In 
schoolchildren, for example, carriage was problematic be-
cause a classmate had a chronic illness and needed regu-
lar hospital checkups. A MRSA-positive family member 
is only problematic in the context of work in healthcare. 
Again, most outbreaks of infectious diseases are problem-
atic within healthcare-associated settings, because these 
outbreaks lead to high morbidity and mortality rates, put-
ting pressure on limited resources and putting HCWs in 
direct danger of contracting disease. Control measures 
for most communicable diseases therefore aim to regulate 
these threats (25). Outbreaks of multidrug-resistant organ-
ism infections, however, do not cause high morbidity and 
mortality rates (21,28–30). Public health measures aim to 
prevent introduction and further transmission of multidrug-
resistant organisms in (some) healthcare-associated settings 
(2). Whether a carrier is subject to control measures does 
not depend on the severity of the pathogen but only on the 
likelihood that the resistant pathogen will be transmitted to 
a healthcare setting where vulnerable patients are cared for.
Multidrug-Resistant Organism Carriage as a State of Being
A salient feature of the inquiries was that carriage could 
last for a long time, making implementation of control 
measures even more burdensome. Some persons were col-
onized for such a long period, some even starting at birth, 
that it could be argued that the resistant microorganism was 
now part of their regular flora. The inquiries showed that, 
after a person receives a diagnosis of being a carrier, the 
label persists. It was often very difficult to eradicate the 
bacteria; moreover, there was no standard for determining 
whether a person was no longer a carrier. From an ethical 
perspective, persistence is particularly salient because in-
evitably, within the open population but also in healthcare 
settings, there will be a substantial group of unidentified 
asymptomatic carriers. Therefore, the severe restrictions 
faced by known carriers may not only be burdensome and 
stigmatizing but may also be considered unfair.
The Carrier as a Nondefining Factor in a Slowly  
Evolving Threat
In all cases analyzed for this study, the individual carrier 
was a possible link in the chain of transmission but cer-
tainly was not a central factor in the emergence and spread 
of multidrug-resistant organisms. The long-term clinical 
effect of multidrug-resistant organisms may be high, but it 
was not obvious that imposing restrictions, either preemp-
tive or reactive, on individual carriers played a crucial role 
in controlling and mitigating that effect. The immediate 
threat posed by individual carriers was limited, certainly if 
compared with the role of conditions caused by other mi-
croorganisms, such as Ebola virus disease or meningococ-
cal meningitis, for which devastating effects become evi-
dent in days, weeks, or months (25).
Discussion
We have shown how multidrug-resistant organism con-
trol measures undermine the well-being of asymptomatic 
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carriers. Although set in a country at the highest end of 
the spectrum with regard to strict AMR control measures, 
this finding is relevant to countries with all types of poli-
cies. The unique ethical features of multidrug-resistant 
organism carriage challenge the way we think about in-
fectious disease control.
Traditionally, epidemics have been portrayed as an 
enemy attack of foreign microbes on human life, describ-
ing the carrier as “patient” or “victim” (25,31). However, 
multidrug-resistant organism carriers are not ill from car-
riage and can remain colonized for a long time. Any role 
as victim results more from the control measures than from 
the pathogen.
AMR control measures that may seem reasonable at 
first can easily lead to stigmatization. Stigma is defined as 
a social process characterized by exclusion, rejection, or 
blame resulting from experience, perception, or anticipa-
tion of adverse social judgments (32). In infectious dis-
ease control, the line between reasonable precaution mea-
sures and stigmatization has always been thin (32–35), 
but when carriage resembles a state of being, with limited 
relevance outside healthcare, the line also becomes vague 
and ambiguous (33).
Still, the dilemma of multidrug-resistant organism 
carriage represents one of the universal ethical challenges 
of public health: balancing the protection of the public 
while respecting individual well-being. Various public 
health ethics frameworks to guide decision-making have 
been suggested in this trade-off (24,36–38). Those frame-
works have in common that they, explicitly or implicitly, 
call for clarity about the goals of a program and evalu-
ation of effectiveness and proportionality. Such clarity 
is indeed valuable, but for multidrug-resistant organism 
control measures, the ultimate goals are not obvious. Of 
course, control measures are meant to control further 
spread of AMR, yet at the same time, overall mortality 
rates caused by multidrug-resistant organisms are still 
low and limited to vulnerable patients. Moreover, AMR is 
not a single epidemic; rather, it is a complex problem that 
slowly evolves and continually reemerges. Types of mi-
croorganisms displaying resistance and resistance mecha-
nisms are constantly evolving. How AMR will emerge 
and what implications it will have in the next decades has 
yet to be determined (39). Although the control of AMR is 
of utmost importance, it is not obvious that strict control 
measures imposed on carriers will make a big difference 
in the overall objective.
AMR resembles a “wicked problem,” a policy chal-
lenge that is not solvable by traditional policy instru-
ments and to which no singular solution exists (8,9). 
Our analysis shows that control measures can be highly 
burdensome to carriers and that the magnitude of bur-
den depends largely on the carrier’s personal situation. 
Tailoring control measures to individual carriers’ needs 
and values may therefore offer a way to deal with the 
wicked complexity.
Rather than asking whether it is justified to impose 
strict control measures to prevent antimicrobial resistance 
transmission from carriers, we propose asking, “How can 
we best care for this person’s carriage and well-being in 
ways that do not imply unacceptable risk (for transmission) 
for other patients?” This question essentially takes an in-
dividualistic and contextual approach, acknowledging that 
different carriers can have different needs and values. For 
instance, some carriers enjoy the privacy that comes with 
isolation, many dislike the solitude, and others are most 
concerned about the quality of care and are relatively indif-
ferent to isolation.
The question touches on the idea of patient-centered 
care, which involves caring for patients (and their fami-
lies) in ways that are meaningful and valuable to each 
patient (40). At the same time, the problem goes beyond 
the scope of healthcare. Often the primary needs of car-
riers are not so much healthcare needs but rather are pro-
tection of the possibility that they can live a good life 
according to their own personal values. From this per-
spective, frameworks that use a rich account of quality of 
life may be helpful for evaluating the justice of control 
measures (41–45).
The question also requires critical reflection on the 
assessment of the risks of possible transmission of AMR 
to others in this specific context, ruling out that control 
measures imposed on individual persons are (implicitly) 
justified by appeal to the general (long-term) public health 
threat of AMR. A specific level of risk may be acceptable 
in a hospital in a region where baseline prevalence is high 
yet problematic in one where prevalence is low.
Especially when strict control measures are justified, 
an individualistic approach can help lower the individual 
burden. A nurse carrying multidrug-resistant organisms 
can be given other tasks instead of being sent home, some 
carriers could be compensated for financial consequences, 
and others could be helped by provision of childcare or 
extra support at home. Relieving the burdens of control 
measures on carriers will often come with financial costs 
for society or healthcare institutions, but it would be unrea-
sonable if burdens of public health measures are borne by 
carriers individually.
In summary, AMR is one of the most severe threats 
of this century and control measures are needed; however, 
these measures are highly burdensome for carriers and of 
only limited benefit to the overall problem. Tailoring mea-
sures to personal needs and values of carriers may offer 
a new way to prevent carriers’ transmission of multidrug-
resistant organisms while minimizing compromises to their 
well-being.
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